Literature DB >> 2548016

Epstein-Barr virus latent infection membrane protein increases vimentin expression in human B-cell lines.

M Birkenbach1, D Liebowitz, F Wang, J Sample, E Kieff.   

Abstract

Latent Epstein-Barr virus (EBV) infection activates B-lymphocyte proliferation through mechanisms which are partially known. One approach to further delineate these mechanisms is to identify cellular genes whose expression is augmented in cells latently infected with EBV. Since EBV-negative Burkitt's lymphoma cells can be grown in continuous culture and EBV can establish growth-altering latent infection in these cells, some effects of EBV on B-lymphocyte gene expression can be studied by using this in vitro system. Pursuing this latter approach, we have used cDNA cloning and subtractive hybridization to identify a gene whose expression is increased after EBV infection. This gene encodes the cytoskeletal protein vimentin. Latent infection of established EBV-negative Burkitt's lymphoma cell lines with the transforming EBV strain, B95-8, resulted in dramatic increases in vimentin mRNA and protein levels, while infection with the nontransforming P3HR1 strain failed to do so. Vimentin induction was reproduced by the expression of the single EBV gene which encodes the latent infection membrane protein (LMP). An amino-terminal LMP deletion mutant did not induce vimentin. These results are of particular interest in light of the transforming potential of LMP, as demonstrated in rodent fibroblasts, and the interaction between vimentin and LMP observed in immunofluorescent colocalization and cell fractionation studies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548016      PMCID: PMC251011          DOI: 10.1128/JVI.63.9.4079-4084.1989

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  DNA of Epstein-Barr virus. III. Identification of restriction enzyme fragments that contain DNA sequences which differ among strains of Epstein-Barr virus.

Authors:  N Raab-Traub; R Pritchett; E Kieff
Journal:  J Virol       Date:  1978-08       Impact factor: 5.103

2.  Epstein-Barr virus-specific RNA. III. Mapping of DNA encoding viral RNA in restringent infection.

Authors:  A L Powell; W King; E Kieff
Journal:  J Virol       Date:  1979-01       Impact factor: 5.103

3.  Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line.

Authors:  T Lindahl; A Adams; G Bjursell; G W Bornkamm; C Kaschka-Dierich; U Jehn
Journal:  J Mol Biol       Date:  1976-04-15       Impact factor: 5.469

4.  Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus.

Authors:  J H Pope; M K Horne; W Scott
Journal:  Int J Cancer       Date:  1968-11-15       Impact factor: 7.396

5.  Identification of antigenic determinants unique to the surfaces of cells transformed by Epstein-Barr virus.

Authors:  C Kintner; B Sugden
Journal:  Nature       Date:  1981-12-03       Impact factor: 49.962

6.  Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes.

Authors:  B F Haynes; M E Hemler; D L Mann; G S Eisenbarth; J Shelhamer; H S Mostowski; C A Thomas; J L Strominger; A S Fauci
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

7.  Epstein-Barr virus latent membrane protein: induction of B-cell activation antigens and membrane patch formation does not require vimentin.

Authors:  D Liebowitz; E Kieff
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

8.  Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference.

Authors:  G Miller; J Robinson; L Heston; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  26 in total

1.  Preferential localization of the Epstein-Barr virus (EBV) oncoprotein LMP-1 to nuclei in human T cells: implications for its role in the development of EBV genome-positive T-cell lymphomas.

Authors:  Jingwu Xu; Ali Ahmad; José Menezes
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.

Authors:  J I Cohen; F Wang; J Mannick; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

3.  A selectable marker allows investigation of a nontransforming Epstein-Barr virus mutant.

Authors:  A Marchini; J I Cohen; F Wang; E Kieff
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

4.  The Epstein-Barr virus BNLF-1 membrane protein LMP1 induces homotypic adhesion mediated by CD11a/CD18 in a murine B-cell line, mimicking the action of phorbol ester.

Authors:  R Salcedo; S M Fuerstenberg; M Patarroyo; G Winberg
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

5.  EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus.

Authors:  N S Sung; S Kenney; D Gutsch; J S Pagano
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

6.  A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1.

Authors:  R Longnecker; E Kieff
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

7.  Epstein-barr virus-induced changes in B-lymphocyte gene expression.

Authors:  Kara L Carter; Ellen Cahir-McFarland; Elliott Kieff
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 8.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; T E Starzl
Journal:  Transplant Sci       Date:  1994-09

9.  CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein-Barr virus-transformed human B cells.

Authors:  M Kryworuckho; F Diaz-Mitoma; A Kumar
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

10.  Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1.

Authors:  F Wang; S F Tsang; M G Kurilla; J I Cohen; E Kieff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.